Jazz Pharmaceuticals PLC (JAZZ) Stock Analysis

Jazz Pharmaceuticals PLC (JAZZ) is a publicly traded company in the HEALTHCARE sector. It trades at $226.12, carries a market capitalization of $14.60B, a price-to-earnings ratio of 1938.67. This page summarizes the public market data, fundamentals, and frequently asked questions for JAZZ, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Jazz Pharmaceuticals PLC currently has a Neutral sentiment score of 0.06.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC is a prominent biopharmaceutical company dedicated to the development and commercialization of innovative therapies that address pressing unmet medical needs, particularly in neurology, rare diseases, and hematology. Based in Dublin, Ireland, the company operates with a strong global presence, enhancing patient care across the United States and Europe. Jazz's extensive pipeline, coupled with its commitment to research and development, underscores its strategic focus o...

GNG Research Analysis

GNG Research scores Jazz Pharmaceuticals PLC (JAZZ) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for JAZZ.

Frequently Asked Questions

Does JAZZ pay dividends?

Jazz Pharmaceuticals PLC (JAZZ) does not currently pay a regular dividend.

What is JAZZ's P/E ratio?

Jazz Pharmaceuticals PLC has a price-to-earnings (P/E) ratio of 1938.67.

What is JAZZ's market cap?

Jazz Pharmaceuticals PLC (JAZZ) has a market capitalization of $14.60B with a current stock price of $226.12.